201 results on '"Anwer, Faiz"'
Search Results
2. Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma
3. Total Body Irradiation Versus Chemotherapy Conditioning in Pediatric Acute Lymphoblastic Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant: A Systematic Review and Meta-Analysis
4. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience
5. Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score
6. The Impact of Atrial Fibrillation on hospitalization Outcomes for Patients With Chronic Lymphocytic Leukemia Using the National Inpatient Sample Database
7. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience
8. Special Considerations for Supportive Care and Management of Complications in Elderly Patients With Multiple Myeloma
9. Primary Mediastinal B-Cell Lymphoma: A 2021 Update on Genetics, Diagnosis, and Novel Therapeutics
10. Emerging Targets and Cellular Therapy for Relapsed Refractory Multiple Myeloma: A Systematic Review
11. Single-Agent Cyclosporine for Graft-versus-Host Disease Prophylaxis in Patients with Acquired Aplastic Anemia Receiving Fludarabine-Based Conditioning
12. Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome–Positive Acute Lymphoblast Leukemia: A Systematic Review
13. Revisiting Role of Vaccinations in Donors, Transplant Recipients, Immunocompromised Hosts, Travelers, and Household Contacts of Stem Cell Transplant Recipients
14. Outcome of Fludarabine-Based Conditioning in High-Risk Aplastic Anemia Patients Undergoing Matched Related Donor Transplantation: A Single-Center Study from Pakistan
15. Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials
16. Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma
17. Prophylaxis for Hepatitis B Virus Reactivation after Allogeneic Stem Cell Transplantation in the Era of Drug Resistance and Newer Antivirals: A Systematic Review and Meta-Analysis
18. Unexpected favorable outcome in a patient with high grade B-cell lymphoma with abnormalities of MYC, BCL6 and BCL2 loci
19. Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas
20. Waldenström Macroglobulinemia: Review of Pathogenesis and Management
21. Clinical Efficacy of Retreatment With Venetoclax-Based Therapy in Relapsed-Refractory t(11;14) Multiple Myeloma
22. Role of Maintenance Therapy after High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Aggressive Lymphomas: A Systematic Review
23. EXPLORING THE EFFECT OF HOSPITAL TEACHING STATUS ON LUNG CANCER OUTCOMES: A POPULATION-BASED ANALYSIS
24. ANALYZING FACTORS, DEMOGRAPHICS, AND OUTCOMES IN MEDIASTINAL TUMOR PATIENTS USING THE NIS DATABASE (2018-2020)
25. BREATHLESS BATTLES: INCIDENCE AND COMPLICATIONS OF ACUTE ASTHMA EXACERBATION IN PATIENTS WITH LUNG CANCER
26. PULMONARY COMPLICATIONS OF BREAST CANCER PATIENTS WITH METASTASIS TO LUNGS: A POPULATION-BASED STUDY
27. MM-039 Unmet Needs Related to Experiences of Myeloma Patients and Their Caregivers and Potential Solutions: A Systemic Literature Review
28. MCL-430 Efficacy of Orelabrutinib in Mantle Cell Lymphoma: A Systematic Review
29. CT-296 Unveiling the Future: Insights From the Current Landscape in Solid Tumor CAR T Clinical Trials
30. MM-433 Efficacy of Isatuximab-Based Regimens Compared to Standard of Care in Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Meta-Analysis of Phase III Clinical Trials
31. MM-297 Impact of MRD Status on Survival Rates in Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients: A Systematic Review and Meta-Analysis
32. Unveiling the Future: Insights From the Current Landscape in Solid Tumor CAR T Clinical Trials
33. Efficacy of Isatuximab-Based Regimens Compared to Standard of Care in Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Meta-Analysis of Phase III Clinical Trials
34. Impact of MRD Status on Survival Rates in Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients: A Systematic Review and Meta-Analysis
35. Unmet Needs Related to Experiences of Myeloma Patients and Their Caregivers and Potential Solutions: A Systemic Literature Review
36. Efficacy of Orelabrutinib in Mantle Cell Lymphoma: A Systematic Review
37. TACTUM: Trends in Access to Cellular Therapies in Multiple Myeloma, Perspectives of Treating Versus Referring Physicians
38. Novel Therapies for De Novo or Relapsed/Refractory AML with TP53 Mutations : A Glimmer of Hope
39. Assessment of Major Adverse Cardiac Events (MACE) and Arrhythmias in Patients with Large B-Cell Lymphoma Undergoing Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Impact of Baseline Cardiac Biomarkers
40. Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
41. Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Anti-B-Cell Maturation Antigen (BCMA)-Exposed Cohort of the CC-220-MM-001 Trial
42. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience
43. Dampening Logistics Creating Inequitable Access: A Major Threat Despite Advancements
44. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience from the US Myeloma Innovations Research Collaborative (USMIRC)
45. Outcomes of BCMA-Directed Chimeric Antigen Receptor T-Cell (CART) Therapy and Teclistamab in Patients with Relapse-Refractory Multiple Myeloma with Extramedullary Disease: A Real-World Experience of the US Myeloma Innovations Research Collaborative (USMIRC)
46. The TACTUM23 Study: Access to Cellular Therapies in Multiple Myeloma: Perspectives of Treating Versus Referring Physicians in 2023
47. Neighborhood Socioeconomic Disadvantage and Distance from Treatment Center Do Not Impact Survival Outcomes of Patients with Non-Hodgkin's Lymphoma (NHL) and Multiple Myeloma (MM) Treated with CAR T-Cell Therapies.
48. Incidence, Characteristics, and Management of Adverse Events with Bispecific T Cell Engagers for Relapsed or Refractory Multiple Myeloma: A Systematic Review
49. A Multicenter Experience: Duration of Mandatory CRS and Icans Monitoring for Myeloma and Lymphoma CAR-T Recipients
50. Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Not Meeting the Karmma-1 Trial Eligibility Criteria: A Real-World Multicenter Study from the US Myeloma Innovations Research Collaborative (USMIRC)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.